Hyperimmune immunoglobulin

Nuvig Therapeutics has dosed the first patient in its Phase 2 INVGOR trial evaluating NVG-2089, a recombinant Fc fusion protein designed to replicate immunomodulatory functions of IVIg for chronic inflammatory demyelinating polyneuropathy (CIDP).

Invivyd has launched a discovery program for a measles monoclonal antibody (mAb) in response to direct requests from healthcare providers treating active measles cases and managing outbreaks.

Sunnybrook scientists made history by non-invasively opening the blood-brain barrier to deliver immunotherapy directly to the brain of an ALS patient using focused ultrasound technology.

Recent clinical data reveals potential risks when transitioning chronic inflammatory demyelinating polyneuropathy (CIDP) patients from intravenous immunoglobulin (IVIg) to efgartigimod, with some experiencing symptom exacerbation during the switch.

Health Canada has expanded marketing authorization for Takeda's HyQvia as a maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults after stabilization with intravenous immunoglobulin.